Agenus Inc (AGEN)

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b study Agenus Inc. (Nasdaq: AGEN), a leader in...

Form 8-K - Current report

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at...

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Noetik’s TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor...

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy Median overall...

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Authorized access interest continues to expand across regions Phase 3 BATTMAN trial commenced patient enrollment in April 2026, advancing...

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 4 - Statement of changes in beneficial ownership of securities